According to the research report titled ‘Global Transcatheter Tricuspid Valve Intervention (TTVI) Market - Analysis By Intervention Type (TVr, TVR), Disease Type (TR, TS), End User, By Region, By Country (2021 Edition): Market Insights, Pipeline, COVID-19 Implications, Competition and Forecast (2021-2030)’, available with MarketStudyReport, global transcatheter tricuspid valve intervention industry is anticipated to garner a significant growth and reach a value of USD 10.17 billion by 2030.

The growth of worldwide transcatheter tricuspid valve intervention industry is credited to the ubiquity of tricuspid valve ailments, especially among the elderly, in consort with preference for transcatheter valvular therapies, and the enhancement in the field on account of technological developments.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4331005/   

Looking at the downside, the COVID-19 pandemic has unwontedly impacted the cardiovascular care industry and other associated industrial sectors. Due to lockdown and stay-at-homes policies, the surgeries were delayed, screenings suspended, and clinical trials & approvals took longer than expected, all of which hampered the industry dynamics.

As per intervention segmentation, the market is categorized into tricuspid valve replacement, and tricuspid valve repair. These segments are poised to grow in the coming years, majorly due to valve repair and replacement approaches are being preferred instead of conventional open-heart operations.

Moving towards the disease spectrum, worldwide transcatheter tricuspid valve intervention industry can be categorized into tricuspid stenosis, and tricuspid regurgitation.

Regionally, Europe market is estimated to accrue massive revenues during the year 2021-25, owing to early consent for new tricuspid valve repair devices, pervasiveness of tricuspid valve diseases, rise in the elderly population, and high spending on healthcare.

On the other hand, Asia-Pacific market is reckoned to grow significantly in the second half of the forecast period during 2026-30, on account of discontented requirement of patients suffering from the disease, fast expansion of healthcare infrastructure, rise in medical tourism, and increasing healthcare investments by public and private sectors.

The leading competitors in the global transcatheter tricuspid valve intervention (TTVI) industry include Abbott Laboratories, LivaNova plc, Venus MedTech HangZhou Inc., 4Tech Cardio Ireland Ltd., HuiHe Healthcare, Edwards Lifesciences, Medtronic plc, CryoLife Inc., Jenscare Scientific Co. Ltd., and NaviGate Cardiac Structures Inc.